Malcolm Hoffman's Stock Ratings

SPY760.97 QQQ687.65+0.35%BTC/USD78,309.00+1.25%DIA525.21+1.58%GLD370.04+3.00%TLT81.45+0.42%

Premium Services

Overall Average Return

-25.6%

Smart Score

Overall Average Return Percentile

8th

Number of Ratings

4

		Buy Now								Get Alert
08/12/2026	LBRX	Buy Now	LB Pharmaceuticals	$39.37	37.16%	Malcolm Hoffman20%	$46 → $54	Maintains	Outperform	Get Alert
07/21/2026	MPLT	Buy Now	MapLight Therapeutics	$6.80	576.47%	Malcolm Hoffman20%	→ $46	Initiates	→ Outperform	Get Alert
07/21/2026	AXSM	Buy Now	Axsome Therapeutics	$140.00	121.43%	Malcolm Hoffman20%	→ $310	Initiates	→ Outperform	Get Alert
07/21/2026	LBRX	Buy Now	LB Pharmaceuticals	$39.37	16.84%	Malcolm Hoffman20%	→ $46	Initiates	→ Outperform	Get Alert

Recent Analyst Stock Rating News

Axsome Therapeutics Q3 2026 Earnings Call Transcript

Axsome Therapeutics Q3 2026 Earnings Call Transcript

Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook